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Introduction
RA is a chronic autoimmune disease affecting about 1%
of the general population. RA is characterized by symmet-
rical inflammation of synovial joints and has often been
classified with a group of organ-specific autoimmune dis-
eases including multiple sclerosis, type 1 diabetes, and
pemphigus vulgaris. RA differs from these diseases in
several aspects, however, and RA patients may develop
extra-arthicular disease manifestations such as rheumatoid
nodules, rheumatic lung disease, and vasculitis, sugges-
tive of a more generalized autoimmune process.
Genetic predisposition to develop RA is strongly associ-
ated with a number of human leukocyte antigen (HLA)
class II alleles, which all share a collection of positively
charged amino acids at positions 70–72 of the DRB1
chain, called the ‘shared epitope’ (reviewed by Winches-
ter [1]). HLA class II molecules function by selecting and
presenting immunogenic peptide epitopes to the CD4+
T cells of the immune system. HLA class II molecules also
have a major role in positive and negative selection in the
thymus of the T-cell receptor (TCR) repertoire released to
the periphery. It has been suggested that these
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mechanisms are in part responsible for the HLA-associ-
ated disease susceptibility in RA and other organ-specific
autoimmune diseases [2].
There are contrasting opinions on how normal immune
regulation breaks down in RA. One opinion argues that
RA is a disease controlled and perpetuated by antigen-
presenting cells (APC), such as dendritic cells,
macrophages, and B cells, and also including convention-
ally nonprofessional APC such as synoviocytes and fibrob-
lasts [3]. The other opinion stresses that CD4+ T cells play
an essential role in sustaining chronic autoimmunity in RA
[4]. Two relatively recent murine models with spontaneous
development of clinical arthritis may provide a reconcilia-
tion of these views and a better understanding of the
mechanisms behind the development of RA [5,6].
The primary disease phenotype detected in several differ-
ent tumor necrosis factor (TNF)-α transgenic mice with
constitutive expression of human TNF has been an inflam-
matory arthritis similar to RA [5,7]. This phenotype is
essentially preserved when these mice are backcrossed to
a severe combined immune deficiency background, which
lacks the development of B cells and T cells, indicating
that arthritis can develop without the participation of
lymphocytes. The importance of TNF-α is further sup-
ported by trials in humans, in which antagonizing TNF-α by
means of anti-TNF-α monoclonal antibodies or TNF recep-
tor antagonists is very effective in controlling arthritis
symptoms, while disease activity usually rebounds if treat-
ment is stopped [8]. It is possible that high local or sys-
temic TNF-α production, for example in connection with
infection, may function as a trigger of disease activity in
RA. However, TNF-α may also exert its function indirectly
through the upregulation of other cytokines [9], and it has
been reported that APC populations in the rheumatoid
joints have strong expression of IL-1β [10].
Spontaneous RA-like arthritis was also observed in a
murine TCR transgenic model, (KRNxNOD) [6]. This TCR
was originally chosen because it was specific for bovine
ribonuclease in the context of I-Ak. The transgenic TCRαβ-
positive cells were completely deleted in I-Ak  mice,
however, and in attempts to rescue the transgenic CD4+
T cells from deletion these mice were crossed to a number
of different inbred mouse strains. Surprisingly, all the TCR
transgene-positive animals developed arthritis within the
first few weeks of life after the first cross to the nonobese
diabetic mouse strain (NOD) [6]. These transgenic T cells
were, in the context of the I-Ag7 allele of the NOD, acti-
vated by a cross-reactive self-protein, glucose-6-phosphate
isomerase (GPI), which is a ubiquitously expressed murine
protein [11]. Transfer of purified GPI-specific autoantibod-
ies from (KRNxNOD) mice could induce arthritis in healthy
mice of the inbred balb/c and C57/B6 strains but not in
mice of the inbred NOD strain, which is deficient in com-
plement factor C′5 [12], and the (KRNxNOD) mice did not
develop arthritis after backcrossing to knockout mice
lacking the B-cell compartment [13]. Although GPI-specific
autoantibodies seem to be essential for arthritis develop-
ment in the (KRNxNOD) model, TCR transgenic CD4 T
cells hold the real key to development of the disease phe-
notype, since the production of the GPI-specific autoanti-
bodies is contingent on the help from CD4 T cells.
In a different TCR transgenic model system investigating
the influenza hemagglutinin (HA)-specific TCR transgenic
model (TS1) crossed with various transgenic lines
expressing the HA as ‘neo-self-antigens’, Cope et al. have
shown that the TCR αβ-positive T cells could change from
a predominantly Th2 phenotype in TS1 single-transgenic
mice to a Th1 phenotype after passing positive and nega-
tive selection in the thymus of the double-transgenic
(TS1xHA) mice [14]. It is well established in several exper-
imental models of inflammatory arthritis that the level of
specific (auto)antibodies of IgG2a subtype, which is
dependent on Th1 help, in the individual animal is directly
correlated to the risk of developing arthritis [15–18]. The
IgG subtype of the GPI autoantibodies has not been
reported in the (KRNxNOD) arthritis model. It is possible,
however, that the T helper cell evolution and the cytokine
response pattern elicited by TCRαβ transgene-positive T
cells on the NOD background are the most important part
of the (KRNxNOD) mice.
GPI-specific autoantibodies, which have undergone
somatic mutation, have been detected in humans with RA
[19]. Although it is unknown what role these autoantibod-
ies play in disease, it is possible that components similar
to those active in the (KRNxNOD) mouse may also be
implicated in the autoimmune process in RA in humans.
In view of the strong genetic association between particu-
lar HLA class II alleles and RA, we assume that CD4+
T cells play a significant role in the pathogenesis of this
disease. CD4+ T cells might supply some sort of general-
ized immune activation similar to the two transgenic arthri-
tis models already mentioned [5,6]. It is possible that the
activation of dendritic cells and macrophages, together
with an upregulation of accessory molecules and homing
receptors locally in the joints, perhaps secondary to infec-
tion, can lower the threshold for activation of autoreactive
Th1 cells. From studies of autoantigen-specific CD4+
T-cell responses in humans, including T-cell proliferation
and different cytokine assays, it is known that not only do
many patients demonstrate autoreactive T-cell responses
in vitro, but autoreactive T-cell responses can also be
detected in healthy control individuals of appropriate HLA
genotype [20–22]. Why do these autoreactive T cells only
rarely cause disease, and what are the differences in the
immune responses of healthy individuals compared with
those of patients with autoimmune diseases?S135
Special cytokine patterns are often taken as an indication
of an activation of a unique T-cell subpopulation. We have
hypothesized that the individual CD4+ T-cell epitopes of a
given autoantigen in the setting of one particular HLA
class II allele in a healthy in vivo study subject would acti-
vate a distinct CD4+ T-cell population. To test this hypoth-
esis, we have studied cytokine responses in healthy
HLA-DR4 transgenic mice after immunization with intact
protein antigen, followed by cytokine measurement after in
vitro re-stimulation with the individual peptide epitopes.
Although immunization with antigen in incomplete Freund’s
adjuvant (IFA) might bias the cytokine responses to a
certain degree, comparative studies using other forms of
immunization with antigen-pulsed dendritic cells or DNA
vaccination should ultimately resolve this problem.
We chose to analyze the CD4 T-cell immune responses to
the human cartilage autoantigen, HCgp-39, in the setting
of the RA-associated HLA-DR*0401 (DRA*0101/
DRB1*0401) HLA class II molecule [23]. To augment the
autoreactive T-cell responses of these mice, a TCRαβ
transgene was added to the model. The TCR construct
was produced from a selected T-cell hybridoma specific
for a HCgp-39 peptide epitope, which induced a signifi-
cant IFN-γ response.
Development of HLA class II transgenic mice
The original HLA class II transgenic mouse model was
designed to serve as an in vivo animal model in which
several aspects of the human CD4+ T-cell immune
responses could be studied after immunization with either
endogenous or exogenous protein antigen [24]. Trans-
genic mice with the RA-susceptible DR*0401 allele and
the RA nonassociated DRA/DRB1*0402 (DR*0402)
allele, which had IDE in place of the QKR sequence of the
‘shared epitope’, were produced using cDNA matching
the entire human coding sequences for the DRA and
DRB1 chains expressed under the direction of the I–E
alpha promoter [25].
To obtain sufficient selection of CD4+ T cells, it was neces-
sary to introduce a correctly expressed human CD4 trans-
gene and to delete the murine major histocompatibility
complex class II genes [24]. This was achieved by cross-
breeding with a human-CD4 transgenic line provided by Dr
D Littman, and the murine class II-negative Aβ line from Dr
D Mathis and Dr C Benoist [26,27]. After these changes,
the cell surface expression of the HLA-DR*0401 molecule
increased two to three times, and the CD4+ T-cell counts
increased accordingly [24]. However, all our HLA class II
transgenic mice, which were carefully selected from
between six and 15 different transgenic founder lines per
HLA specificity, had preserved normal lymphoid architec-
ture and correct tissue-specific expression of the intro-
duced HLA molecules in the thymus, the lymph nodes and
the spleen. These mice had normal CD4+ T-cell function
and, similar to HLA-DR4+ humans, they did not develop
spontaneous autoimmune diseases [24].
Choice of human autoantigen
The human cartilage protein HCgp-39 was chosen as a
model autoantigen because it was a proven target for T-cell
autoimmunity in RA patients [23,28]. A significant fraction
of RA patients had shown signs of previous T-cell activa-
tion specific for a number of the immunogenic peptides
from the protein, suggesting that it might be a possible
target for future immunotherapy in RA. Our choice of proto-
type antigen, however, did not imply that HCgp-39 was
supposed to have a unique role in the pathogenesis of RA.
Epitope mapping of HCgp-39 protein in HLA-DR*0401
and HLA-DR*0402 transgenic mice
CD4+ T-cell epitope mapping after immunization of
DR*0401 and DR*0402 transgenic mice with recombi-
nant HCgp-39 in IFA was performed using the T-cell
hybridoma technique, which is described in detail in Cope
et al. [23]. These experiments, involving 16 HLA-DR*0401
and 12 HLA-DR*0402 transgenic mice of appropriate
genotypes, revealed three major immunogenic HCgp-39
epitopes (peptides 100–115, 262–277, and 322–337) in
DR*0401 mice and two major epitopes (peptides 22–37,
and 298–313) in DR*0402 mice [23]. A number of minor
HCgp-39-specific T-cell epitopes were also identified
[23]. Investigation of peptide–HLA complex stability for
the major immunogenic HCgp-39 epitopes showed that
the immunogenicity of DR*0401 and DR*0402 peptide
epitopes was strongly related to the kinetic stability in all
conditions, from the acidic endosomal compartment in the
presence of the peptide editor HLA-DM to the neutral cell
surface conditions [29].
HCgp-39-specific cytokine production in HLA-DR*0401
transgenic mice
Early cytokine studies in DR*0401 and DR*0402 trans-
genic mice had shown that intact HCgp-39 protein
elicited strong IFN-γ and TNF-α responses in DR*0401
transgenic mice, while fairly small IFN-γ responses were
detected in the DR*0402 transgenic mice [23]. TNF-α
responses were not detected in the DR*0402 transgenic
mice after in vivo immunization with HCgp-39 [23]. The
intact HCgp-39 protein, as well as the individual HCgp-39
peptides, induced only small amounts of IL-2 in DR*0401
transgenic mice (Hall F, manuscript in preparation).
Two immunodominant peptide epitopes (peptides
100–115 and 322–337) appeared to be responsible for
the majority of the IFN-γ elicited in response to HCgp-39
immunization. The Th2-type cytokine IL-5, however, was
predominantly generated by peptide 100–115, while mod-
erate amounts of TNF-α and intermediate levels of IL-10
could be driven by either peptide 100–115 or peptide
322–337 (Hall F, manuscript in preparation). The third
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major epitope (peptide 262–277) elicited small amounts
of each of the five cytokines tested, and the significance of
this reactivity pattern is unknown.
The bulk of the TNF-α was produced in response to the
two minor peptide epitopes, peptides 256–271 and
334–349 (Hall F, manuscript in preparation). Considering
the low frequencies of T cells responding to these two
peptide epitopes [23], this response was (on a per-cell
basis) approximately 50 times higher than the TNF-α pro-
duced in response to peptides 100–115 and 322–337.
On a per-cell basis, peptides 256–271 and 334–349
elicited about the same IFN-γ levels as peptide 322–337,
but no IL-5 or IL-10 responses were detected after re-
stimulation with either of these ‘minor’ peptides (Hall F,
manuscript in preparation).
The two T-cell epitopes 256–271 and 334–349 had been
selected for further studies because they had elicited T-
cell proliferative responses in the majority of both the HLA-
DR4-positive RA patients and the HLA-DR4-positive
human control subjects studied [23] (Sønderstrup G,
unpublished results, 1998). Peptides 256–271 and
334–349 may therefore activate a unique subset of CD4
T cells. However, it should be emphasized that HCgp-39
functioned as a foreign antigen in the HLA-DR*0401
transgenic mice, while it was a self-protein in humans.
Cytokine responses after immunization with synthetic
peptide versus intact protein antigen
Since a major objective was to identify a TCR for produc-
tion of TCR transgenic mice in which disease might be
induced, we chose to focus on peptide epitope 322–337
that exhibited a Th1 cytokine pattern. Figure 1a shows the
IFN-γ response of four individual HLA-DR*0401+/human
CD4+/murine I-Aβ–/– mice after immunization with recom-
binant HCgp-39 protein in IFA followed by in vitro re-stim-
ulation with medium only (control), intact HCgp-39 protein
(20 µg/ml), and the specific peptide 322–337 (10 µg/ml)
for 24, 48, and 74 hours. Three of the four mice produced
high IFN-γ levels to both protein and peptide, while mouse
1 responded much less (Fig. 1a).
In a similar study of four additional DR*0401 transgenic
mice that were immunized with the synthetic peptide
322–337, 100 µg in IFA (Fig. 1b), lymph-node T cells
preferentially responded with high levels of IFN-γ to the
synthetic peptide itself. The IFN-γ responses to intact
HCgp-39 protein were about 10 times lower (Fig. 1b).
These data suggest that the responding CD4+ T-cell pop-
ulation activated in vivo following immunization with a syn-
thetic peptide may be different from the T-cell population
responding to the same amino acid sequence if
processed from the native protein antigen. T-cell clones
that recognize the same peptide–HLA complex, which will
only respond after in vitro re-stimulation with the synthetic
peptide but not the intact protein antigen, have been
described earlier as type b T cells [23,30]. In a recent
study of antigen processing and presentation of the
immunodominant HCgp-39 epitopes using HLA-DM-posi-
tive and HLA-DM-negative human APC, we have also
shown that intact HCgp-39 protein must be processed via
the endosomal compartment in the presence of HLA-DM
molecules to induce activation of the peptide 322–337-
specific T-cell hybridoma clones [31].
TCR transgenic mice specific for peptide 322–337 in the
context of HLA-DR*0401
Detailed studies of more than 10 T-cell hybridomas,
including antigen titration, N-terminal and C-terminal trun-
cation studies as well as a complete set of alanine-substi-
tuted peptides across the wild-type sequence of peptide
322–337, revealed that although all the peptide
322–337-specific T-cell hybridomas recognized the same
peptide–HLA complex, they fell into two groups with dis-
tinct response patterns (Hall F, manuscript in preparation).
Approximately one-half of the T-cell hybridomas were com-
pletely unaffected by alanine substitutions outside of the
9mer core epitope. The second group of the peptide
322–337-specific T-cell hybridomas produced less IL-2,
and these hybridomas usually required a relatively high
antigen concentration. The latter group of T cells was sen-
sitive to both alanine substitutions in the 9mer core region
of the peptide that bound in the groove of the HLA-
DR*0401 molecule and to substitutions in the N-terminal
overhanging amino acids. These residues were presum-
ably TCR contact residues since they only influenced T-
cell responsiveness and had no influence on peptide–HLA
binding (Hall F, manuscript in preparation).
We consequently chose to produce two separate TCR αβ
constructs using a T-cell hybridoma representing each of
these two different response patterns. The two TCR α-
chain and TCR β-chain constructs were produced using
the pTαcass and the pTβcass kindly provided by D Mathis
and C Benoist [32]. The first TCR αβ construct,
TCR/18B1, which was produced using a T-cell hybridoma
from the N-terminal overhang-dependent group, was
TCRVα11, Vβ14. Six TCR transgenic founders transmit-
ting at least the TCR β-chain transgene were obtained.
The 18B1/TCR β-chain was selected both by I-Aq and
DR*0401+ mice. Three of these lines have been tested on
the DR*0401 background and they all responded to both
the nominal peptide and the HCgp-39 protein.
FACS analyses demonstrated that the transgenic TCRVβ-
chain was expressed on more than 95% of CD4+ T cells.
Less than 1% of the T cells expressed other TCRV β-
chains. However, the transgenic T cells did not show an in
vivo activated phenotype. The founder lines of TCR/18B1,
which are still in an early stage of evaluation, will be tested
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for incorporation of the appropriate TCRVα-chain by
means of polymerase chain reaction using specific
primers. DR*0401/peptide 322–337 tetramers are under
development and will be used to determine the exact
levels of expression of the transgenic TCRαβ combination.
The second TCR transgene, 14H2, was TCRVβ6. Unex-
pectedly, the 14H2/TCR was only selected on an I-Aq-
positive background. Several transgenic founder lines
expressing and transmitting the TCR transgene were
obtained. When these mice were backcrossed to the
DR*0401/human CD4/I-Aβ–/– genetic background,
however, no Vβ6-positive T cells (0–1%) could be
detected in the periphery. Non-TCR transgenic littermates
with the full DR*0401+/human CD4+/I-Aβ–/– genotype
usually express between 2 and 5% Vβ6-positive T cells. It
is currently unclear whether the absence of Vβ6-positive T
cells in these mice is due to a lack of positive selection or
due to a complete deletion of the T cells expressing the
transgenic TCRVβ6 chain by thymic negative selection.
To rescue the 14H2/TCR transgene, founder lines that
express transgenic TCRVα and Vβ chains on the I-Aq
genetic background will be backcrossed to an HLA-
DR*0401+ transgenic line on the NOD genetic back-
ground, which is less efficient in negative selection.
Inhibition studies have shown that the 14H2 T-cell
hybridoma exclusively interacts with the human CD4 mole-
cule (Sønderstrup G, unpublished results, 2001), and
separate attempts to rescue thymic selection of the trans-
genic 14H2/TCR are in progress by crossing the
14H2/TCR transgene onto a DR*0401+/I-Aβ–/–/DBA/1J
background without human CD4. Finally, the 14H2/TCR
transgene will also be crossed with HLA-DR*0405 trans-
genic mice on the NOD background. The HLA-DR*0405
allele, which is closely related to the DR*0401 allele, is
also associated with susceptibility to RA [2].
HCgp-39 transgenic mice
The human HCgp-39 protein [33] and the murine counter-
part, Brp39 [34], show more than 80% sequence homol-
ogy, but they differ significantly in the areas that are found
to be important for T-cell recognition in HLA-DR*0401
transgenic mice [24]. We therefore produced transgenic
mice carrying the human HCgp-39 protein expressed
under the murine collagen type II promoter (CoII), which
directs expression to the synovial joints and the eye [35].
An optimal founder line for the CoII-HCgp-39 mice was
identified after intercrossing with DR*0401+/human
CD4+/I-Aβ–/– mice by following the HCgp-39 protein
content of synovial joint cartilage over three generations.
Since the CoII-HCgp-39 transgene functioned as a neo-
self-antigen, the DR*0401 transgenic mice were tolerant
to HCgp-39. However, they did break tolerance and
developed specific antibodies of IgG1, IgG2a, and IgE
isotypes after sequential immunization with HCgp-39 in
complete Freund’s adjuvant followed by immunizations in
IFA (Hall F, manuscript in preparation). We expect to find
a qualitative difference in the HCgp-39-specific immune
responses of DR*0401/CoII-HCgp-39 double-transgenic
mice compared with DR*0401 single transgenic mice.
Future prospects: strategies for triggering in
vivo activation of the TCR α αβ β? transgenic T cells
FACS analysis using anti-CD25, anti-CD44, and anti-
CD69 monoclonal antibodies does not indicate increased
levels of activated CD4+ T cells in the DR*0401+,
18B1/TCR double-transgenic mice. One major objective is
thus to activate the CD4+ T cells carrying the transgenic
Available online http://arthritis-research.com/content/4/S3/S133
Figure 1
(a) IFN-γ responses following immunization with HCgp-39 protein. The IFN-γ responses of four different DR*0401 transgenic mice immunized with
recombinant HCgp-39 in incomplete Freund’s adjuvant following in vitro re-stimulation with either intact protein or immunodominant peptide
epitope 322–337. (b) IFN-γ responses following immunization with peptide 322–337. The contrasting IFN-γ responses elicited by either intact
protein antigen or peptide 322–337 after immunization of four similar DR*0401 mice with the synthetic peptide 322–377 itself.
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TCRαβ combination of these mice in vivo, and this might
be achieved by simple immunization with the HCgp-39
protein or the cognate peptide. However, an immunization
approach may be hampered by processing problems or by
reverse effects of other HCgp-39 T-cell epitopes. Two sep-
arate strategies will therefore be pursued in parallel. The
first uses transgenic mice carrying a tetracycline-inducible
TNF-α transgene expressed under the murine CoII, which
theoretically should induce local activation of the APC
similar to the TNF-α transgenic mice [5]. Founder mice are
currently under selection. A second transgenic approach
will target the peptide 322–337 sequence to the endoso-
mal compartment of professional APC. This approach will
use a DNA construct that substitutes the oligonucleotide
sequence of peptide 322–337 for the CLIP sequence of
the murine invariant chain and insert this cDNA into a modi-
fication of a murine invariant chain cassette vector devel-
oped by D Mathis and C Benoist [36].
Different combinations of these humanized mice will be
used to explore whether clinical arthritis can be induced in
mice by triggering the APC with local TNF-α release
(group 1A), by activating the transgenic TCR with its spe-
cific antigen/peptide as a vaccination in CFA (group 2A),
or by in vivo activation of the TCR transgene by crossing
with a transgenic line (group 3B), which expresses the
cognate peptide as a transgene under the invariant chain
promoter. Mice of the genotypes show in Table 1 will be
monitored in groups of 10 mice for development of clinical
arthritis up to 30 weeks of age.
Assuming that the control mice (groups 1B, 2B, and 3C)
will not develop disease spontaneously, occurrence of
arthritis in mice of group 1A will suggest a major role for
local APC in the development of arthritis. Arthritis after
immunization of group 2A mice will imply a major role for
CD4 T cells in arthritis development. Arthritis in group 3A
mice, which carry the HCgp-39 epitope as a neo-self-
antigen both in the APC (expressed under the invariant
chain promoter) and locally in the joints (expressed under
the CoII promoter), but not in group 3B mice, which only
express the HCgp-39 epitope in the APC, will indicate
that joint antigen-specific CD4 T cells may be very impor-
tant in disease induction. Arthritis in group 3B mice, but
not in group 3A mice, will suggest that high local expres-
sion of autoantigen plays a key role in keeping self-reactiv-
ity in check. Finally, arthritis occurrence in both group 3A
and group 3B mice will indicate that generalized immune
activation plays a major role in RA.
Concluding remarks
This HLA-DR*0401 transgenic mouse model was
designed to provide an in vivo animal model that would
faithfully replicate certain aspects of an HLA-DR*0401-
positive human CD4 T-cell immune system, and therefore
these mice were not expected to develop arthritis or other
autoimmune disease manifestations spontaneously.  The
addition of a neo-self-antigen, the human autoantigenic
protein HCgp-39, which in humans can be produced by
several different cell types in many different tissues during
inflammatory conditions, was expected to provide antigen
specificity to the autoimmune responses of these human-
ized mice.  As outlined in Table 1, the further addition of
the HCgp-39-specific TCR transgene was anticipated to
enlarge the autoantigen-specific Th1 response to this
human neo-self-antigen.  A small population of TCR trans-
gene-positive cells, which may have escaped negative
selection in the thymus but later encounter their specific
peptide presented in the periphery in the context of HLA-
DR*0401 molecules, may then be activated and expanded
Arthritis Research    Vol 4 Suppl 3 Eming et al.
Table 1
Genotypes of experimental animal groups
Group Genotype
1A DR*0401+/human CD4+/Aβ–/–, 18B1/TCR, CoII-HCgp-39, TET-CoII-TNF-α
1B DR*0401+/human CD4+/Aβ–/–, 18B1/TCR, CoII-HCgp-39 Control group
2A DR*0401+/human CD4+/Aβ–/–, 18B1/TCR, CoII-HCgp-39 HCgp-39 in IFA
2B DR*0401+/human CD4+/Aβ–/–, 18B1/TCR, CoII-HCgp-39 Control group
3A DR*0401+/human CD4+/Aβ–/–, 18B1/TCR, CoII-HCgp-39, Ii-HCgp-39
3B DR*0401+/human CD4+/Aβ–/–, 18B1/TCR, Ii-HCgp-39
3C DR*0401+/human CD4+/Aβ–/–, 18B1/TCR Control group
The table shows the detailed genotypes of the different groups of multitransgenic mice that will be used to explore the influence of joint-specific
CD4 T cells in the development of inflammatory arthritis in the humanized in vivo mouse model. Coll, collagen type II promoter; HCgp39, human
cartilage glycoprotein 39; IFA, incomplete Freund’s adjuvant; Ii, invariant chain; TET, tetracycline-inducible TNF-α transgene. S139
in the lymph nodes and the spleen. These humanized mice
would be expected to reproduce some of the most impor-
tant features of human RA and provide a model of
inducible arthritis, which alone or in connection with cell
transfer experiments can be used to develop and pretest
vaccine-like immunomodulatory therapies for AR in humans.
Glossary of terms
Coll = collagen type II promoter; DM = HLA-DM, a non-
peptide-binding HLA class II molecule, which facilitates
exchange of peptides of already formed peptide/HLA
class II complexes, mostly in the acidic endosomal com-
partment of the antigen-presenting cell; GPI = glucose-6-
phosphate isomerase; HA = influenza hemagglutinin;
HCgp-39 = human cartilage glycoprotein 39; HLA-
DR*0401 = DRA, DRB1*0401; HLA-DR*0402 = DRA,
DRB1*0402; HLA-DR*0405 = DRA, DRB1*0405; IFA =
incomplete Freund’s adjuvant; NOD = nonobese diabetic
(mouse); TS1 = influenza hemagglutinin-specific TCR
transgenic model.
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